Stay updated on Birinapant and Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Birinapant and Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the Birinapant and Pembrolizumab in Solid Tumors Clinical Trial page
- CheckyesterdayChange DetectedThe site footer revision identifier changes from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check8 days agoChange DetectedThe ClinicalTrials.gov record for the birinapant and pembrolizumab study is now displayed, with its study design, eligibility criteria, outcomes, locations, and record history. It states that the trial was terminated and enrollment stopped following a futility analysis.SummaryDifference57%

- Check15 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedAn NIH transition notice was added above the ClinicalTrials.gov 403 error page, and the displayed site revision changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check43 days agoChange DetectedThe site revision identifier in the footer changed from v3.7.0 to v3.7.1. The study record remains inaccessible behind a 403 Forbidden error.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the prior study record content and removing the trial details from view.SummaryDifference19%

Stay in the know with updates to Birinapant and Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Birinapant and Pembrolizumab in Solid Tumors Clinical Trial page.